ArticleTransplantation2026
Not all Mismatches Were Created Equal: Empirical Identification of Regions Within HLA-DQ Molecules That Harbor the Highest Immunogenicity.
Article in Transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A multicenter kidney transplantation study identifies hierarchy and directionality of HLA-DQ alloimmune responses.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHLA-DQ mismatches between donor and recipient confer the highest risk for generation of donor-specific antibodies leading to poor allograft survival. Therefore, understanding hierarchical immunogenicity of HLA-DQ mismatches is needed to guide risk stratification.
methodsAdsorption/elution experiments were optimized using homozygous cell lines as targets. Serum samples from transplant recipients studied herein were limited to those obtained at first documentation of de novo HLA-DQ donor-specific antibodies.
resultsThe use of different HLA-DQ targets in optimized adsorption/elution experiments allowed for separation of sera exhibiting polyclonal antibody reactivity into individual antibodies recognizing epitopes with monospecificity. Our heterogeneous cohort demonstrated only a small repertoire of amino acids, or regions of interest, associated with the initial HLA-DQ humoral response. Most of the mismatches listed in the HLA Eplet Registry did not participate in these first-tier responses. Adsorption/elution studies were instrumental in documenting epitope spreading in patients with broadening of HLA-DQ antibody repertoire, highlighting the occurence of a first-tier response before triggering additional immune responses. Finally, first-tier regions of interest correlate with first-field (low-resolution) HLA typing, namely conventional serologic HLA-DQ antigen families, enriched with DQα chains specificity.
conclusionsThese findings clearly demonstrate that some "molecular mismatches" are more immunogenic than others. They further support our previous observations documenting increased risk of HLA-DQα*05 heterodimer mismatches and provide a tool to continue interrogating differential immunogenicity. Finally, we provide guidance to identify high- and low-risk HLA-DQ mismatches. Taken together, our study supports a different conceptual and experimental framework to study HLA-DQ immunogenicity, and an immunological rationale to guide risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.